Aldosterone breakthrough does not alter central hemodynamics

INTRODUCTION: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are widely used in congestive heart failure and chronic kidney disease, but up to 40% of patients will experience aldosterone breakthrough, with aldosterone levels rising above pre-treatment levels after 6–12 mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Beenken, Andrew, Bomback, Andrew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843861/
https://www.ncbi.nlm.nih.gov/pubmed/28992758
http://dx.doi.org/10.1177/1470320317735002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843861/
https://www.ncbi.nlm.nih.gov/pubmed/28992758
http://dx.doi.org/10.1177/1470320317735002

Ejemplares similares